DataM Intelligence | competitive Intelligence Emerging TED therapies aim to outpace Tepezza with safer, more convenient, and longer-lasting ...

Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

Discover key insights from Roivant Sciences' Q4 2024 earnings call. Learn about their robust pipeline, pivotal 2025 milestones, and capital strength.

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) while keeping the price target the same at $18. The reiteration comes after the company appointed ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Roivant's pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small ...

EMERYVILLE, Calif., May 08, 2025--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner ...

Batoclimab Immunovant announced positive study results for batoclimab in MG and CIDP. The pivotal study in MG met its primary endpoint, showing a change from baseline in the Myasthenia Gravis ...

Additionally, the company is expecting results from another drug, batoclimab, for Graves’ disease. This will include data on patients who would stay in remission for 6 months without treatment ...